Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
  • PRODUCT DEVELOPMENT
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL
      • CHRONIC PAIN
      • INSOMNIA
      • AUTISM
  • MEDICAL CANNABIS
    • SCIENCE
    • LEGALISED MARKETS
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
  • PRODUCT DEVELOPMENT
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL
      •                 - CHRONIC PAIN
      •                 - INSOMNIA
      •                 - AUTISM
  • MEDICAL CANNABIS
    •         - SCIENCE
    •         - LEGALISED MARKETS
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

Viriathus Research Report, 13 September 2018

By zeldaadminJanuary 24, 2019report

Viriathus Research Report, 13 September 2018

Prescription Opioid Crisis
March 2019 Quarterly Report

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics
8 Jul

Zelira is undertaking product development programs targeting specific conditions (e.g. HOPE™) and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain. #ZLD #insomnia #clinicaltrial #stockmarket #pain

Load More...

CONTACT US






Copyright © Zelira Therapeutics. All rights reserved.